Breaking News Instant updates and real-time market news.

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

20:25
12/04/16
12/04
20:25
12/04/16
20:25

Canaccord biotech analyst to hold a dinner meeting

In conjunction with the 58th Annual ASH Meeting, Biotech Analyst Newman hosts a Key Opinion Leader Dinner Meeting with Raajit Rampal, MD, who discusses the implications for Incyte (INCY), Pfizer (PFE) and Eli Lilly (LLY) on December 4 at 8:30 pm.

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

  • 04

    Dec

  • 15

    Dec

INCY Incyte
$102.02

2.09 (2.09%)

11/17/16
LEER
11/17/16
NO CHANGE
Target $115
LEER
Outperform
Incyte price target raised to $115 from $101 at Leerink
Leerink analyst Michael Schmidt raised his price target for Incyte (INCY) to $115 from $101 after Gilead (GILD) reported disappointing top-line results from two Phase III studies evaluating momelotinib, its JAK1/2 inhibitor for patients with myelofibrosis. The analyst believes that the removal of this uncertainty on the revenue outlook of Incyte's key commercial product, combined with increasing prospects of a repatriation holiday should make the company more attractive as an acquisition target. He reiterates an Outperform rating on Incyte's shares.
11/17/16
BMOC
11/17/16
NO CHANGE
BMOC
Incyte drug won't have 'meaningful competition,' says BMO Capital
BMO Capital analyst M. Ian Somaiya says that "mixed data" on Gilead's (GILD) momelotinib in myelofibrosis eliminates any "meaningful competition" faced by Incyte's (INCY) Jakafi in the disease. The analyst raised his price target on Incyte to $126 from $121 and keeps an Outperform rating on the shares.
11/18/16
RHCO
11/18/16
NO CHANGE
RHCO
Incyte has several positive catalysts, says SunTrust
SunTrust analyst PEter Lawson says he expects Incyte's baricitinib, which he calls a key profitability driver for the company, to be approved by the FDA next quarter. He also expects the company to benefit from positive data on its epacadostat and IOs in solid tumor settings. The analyst keeps a Buy rating on the shares.
11/18/16
GABE
11/18/16
NO CHANGE
Target $99
GABE
Buy
Incyte, Regeneron among Gilead M&A options after latest setback, says Gabelli
Gabelli analyst Jing He noted Gilead's (GILD) "mixed" results from its Phase III trials evaluating momelotinib, which showed that the drug is not superior to Incyte's (INCY) Jakafi. Commenting on Gilead's potential path after momelotinib's "disappointing" results and several other pipeline setbacks this year, He suggested that Gilead could look to buy Incyte, which looks like "Regeneron lite," or simply buy Regeneron (REGN) itself. The analyst said Gilead could alternately target an orphan drug company such as Alexion (ALXN), Vertex (VRTX) or BioMarin (BMRN). She keeps a Buy rating and $99 per share private market value on Gilead shares, as she expects M&A to be a catalyst for the stock.
PFE Pfizer
$31.63

0.17 (0.54%)

11/29/16
11/29/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Overweight from Equal Weight at Barclays with analyst Geoff Meacham saying he sees a greater likelihood that Pfizer will be able to access its cash overseas under the new administration, which could be used to acquire growth assets and return capital to shareholders. 2. Comerica (CMA) upgraded to Outperform from Market Perform at Keefe Bruyette. 3. Tractor Supply (TSCO) upgraded to Buy from Neutral at Northcoast with analyst Chuck Cerankosky saying he expects the company to benefit from colder weather and the improving US economy and said product assortments and promotions have also been adjusted to the new economics of the energy patch and its impact on this company's customers. 4. Del Frisco's (DFRG) upgraded to Outperform from Neutral at Credit Suisse with analyst Jason West saying it is a key beneficiary of improved high-end consumer and corporate spending. 5. Veracyte upgraded to Buy from Neutral at Janney Capital with analyst Paul Knight saying the company's "disciplined test development, commercialization, and reimbursement processes" insulate it from a number of problems plaguing the pharma sector. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/02/16
12/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Exxon Mobil (XOM) initiated at BMO Capital. 2. Pfizer (PFE) initiated with a Neutral at Guggenheim. 3. DuPont Fabros (DFT) initiated with a Neutral at Guggenheim. 4. Acadia (ACHC) resumed with a Buy at Jefferies. 5. Shire (SHPG) initiated with a Buy at Societe Generale. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/02/16
GUGG
12/02/16
INITIATION
GUGG
Neutral
Pfizer initiated with a Neutral at Guggenheim
11/29/16
LEHM
11/29/16
UPGRADE
Target $38
LEHM
Overweight
Pfizer upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Geoff Meacham upgraded Pfizer to Overweight and raised its price target to $38 from $37. Meacham sees a greater likelihood that Pfizer will be able to access its cash overseas under the new administration, which could be used to acquire growth assets and return capital to shareholders.
LLY Eli Lilly
$67.71

1.74 (2.64%)

11/28/16
SBSH
11/28/16
DOWNGRADE
Target $60
SBSH
Neutral
Citi analyst 'perturbed,' downgrades AbbVie to Neutral
Citi analyst Andrew Baum earlier today downgraded AbbVie (ABBV) to Neutral from Buy and lowered his price target for the shares to $60 from $65. The biopharmaceutical company is trading down 2%, or 99c, to $59.52. The risk to post 2017 consensus estimates for Humira has "increased on almost all fronts," Baum tells investors in a research note. The analyst sees increased patent risk and competition from biosimilar Enbrel in Europe. He also believes AstraZeneca (AZN) and Acerta's acalabrutinib "looks like a better mousetrap" than AbbVie's Imbruvica. Baum is also "perturbed" by AbbVie management's recent "rich" acquisition of Stemcentrx. He prefers shares of Eli Lilly (LLY) and Bristol-Myers (BMY) to AbbVie.
12/02/16
EVER
12/02/16
NO CHANGE
EVER
Hold
Eli Lilly expanded indication bodes well for Jardiance growth, says Evercore ISI
Evercore ISI analyst John Scotti said the FDA approval of Jardiance's sNDA for the reduction of CV mortality allows Eli Lilly's salesforce to directly promote the CV death indication, which he believes bodes well for the growth of the Jardiance franchise. The company, which has maintained that updates to the label and treatment guidelines expected in 2017 are likely to cause an inflection in the drug's sales, said the updated label should be on-line by next week, added Scotti, who has a Hold rating on Lilly shares.
12/02/16
GSCO
12/02/16
NO CHANGE
Target $82
GSCO
Buy
Jardiance CV death risk reduction indication a positive for Lilly, says Goldman
Goldman Sachs analyst Jami Rubin said his estimate, and the current consensus estimate, for Jardiance sales assumed that Eli Lilly (LLY) would get a new indication for Jardiance to reduce the risk of cardiovascular death in type 2 diabetes patients, but he still views the news as positive for sentiment given some investor nervousness and the recent solanezumab disappointment. The indication differentiates Jardiance from Johnson & Johnson's (JNJ) Invokana and AstraZeneca's (AZN) Farxiga, adds Rubin, who has a Buy rating and $82 price target on Lilly shares.
11/28/16
MAXM
11/28/16
NO CHANGE
Target $15
MAXM
Buy
Anavex may be targeting 'ideal approach' to Alzheimer's disease, says Maxim
After Eli Lilly's (LLY) solanezumab failed its third Phase 3 study in early-stage Alzheimer's disease, Maxim analyst Jason McCarthy noted that Anavex's (AVXL) 2-73 targets the disease "more broadly upstream" to restore proper CNS cell function and has shown "promising early data." While too soon to draw any firm conclusions, given the lessons learned from failures in pursuit of other avenues, Anavex "may be on the right track" by looking upstream, said McCarthy, who keeps a Buy rating and $15 price target on the stock.

TODAY'S FREE FLY STORIES

CIVB

Civista

$22.15

0.04 (0.18%)

21:13
02/21/17
02/21
21:13
02/21/17
21:13
Syndicate
Civista 1.4M share Secondary priced at $21.75 »

Keefe Bruyette and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TJX

TJX

$76.24

-0.95 (-1.23%)

, SO

Southern Company

$48.28

0.48 (1.00%)

20:25
02/21/17
02/21
20:25
02/21/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TJX

TJX

$76.24

-0.95 (-1.23%)

SO

Southern Company

$48.28

0.48 (1.00%)

DISH

DISH

$62.82

-0.07 (-0.11%)

HST

Host Hotels

$18.69

0.3 (1.63%)

NCLH

Norwegian Cruise Line

$48.20

0.51 (1.07%)

MBLY

Mobileye

$46.12

0.47 (1.03%)

GRMN

Garmin

$50.45

-0.36 (-0.71%)

TOL

Toll Brothers

$31.99

0.5 (1.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

MNTA

Momenta

20:19
02/21/17
02/21
20:19
02/21/17
20:19
Downgrade
Momenta rating change  »

Momenta downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

MNTA

Momenta

$16.05

-2.95 (-15.53%)

20:19
02/21/17
02/21
20:19
02/21/17
20:19
Downgrade
Momenta rating change  »

Momenta downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

SNAP

Snap Inc

20:00
02/21/17
02/21
20:00
02/21/17
20:00
Periodicals
Goldman Sachs: Snap revenue could hit $2B in 2018, Business Insider reports »

Goldman Sachs, one of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

BA

Boeing

$175.56

2.85 (1.65%)

19:55
02/21/17
02/21
19:55
02/21/17
19:55
Periodicals
Boeing attempts to accelerate satellite manufacturing process, WSJ says »

Boeing is working to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

DBOEY

Deutsche Boerse

$8.64

0.065 (0.76%)

19:50
02/21/17
02/21
19:50
02/21/17
19:50
Periodicals
Deutsche Boerse, LSE set to offer additional merger concessions, FT says »

Deutsche Boerse and LSE…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$133.72

0.19 (0.14%)

19:35
02/21/17
02/21
19:35
02/21/17
19:35
Periodicals
Facebook nears deal to expand European headquarters, Bloomberg says »

Facebook is nearing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 28

    Feb

  • 06

    Mar

  • 19

    Mar

  • 28

    Mar

GOOG

Alphabet

$831.66

3.59 (0.43%)

, GOOGL

Alphabet Class A

$849.27

2.72 (0.32%)

19:25
02/21/17
02/21
19:25
02/21/17
19:25
Periodicals
Google to discontinue 'Google Site Search,' Fortune says »

Google plans to…

GOOG

Alphabet

$831.66

3.59 (0.43%)

GOOGL

Alphabet Class A

$849.27

2.72 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 23

    Feb

  • 06

    Mar

  • 19

    Mar

WMT

Wal-Mart

$71.45

2.08 (3.00%)

19:20
02/21/17
02/21
19:20
02/21/17
19:20
Periodicals
Wal-Mart adds some in-house brands to Jet.com, Bloomberg says »

Wal-Mart subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 06

    Mar

  • 14

    Mar

  • 19

    Mar

AAPL

Apple

$136.70

0.98 (0.72%)

19:13
02/21/17
02/21
19:13
02/21/17
19:13
Hot Stocks
Analytics firm: Average U.S. iPhone user spent $40 on apps in 2016 »

Analytics firm Sensor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

AMZN

Amazon.com

$856.44

11.37 (1.35%)

19:05
02/21/17
02/21
19:05
02/21/17
19:05
Periodicals
Amazon to sell beer, wine in 'Amazon Go' store, Recode says »

Amazon plans to sell beer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 14

    Mar

  • 19

    Mar

  • 28

    Mar

ARII

American Railcar

$46.03

-0.62 (-1.33%)

, IEP

Icahn Enterprises

$54.95

-1.03 (-1.84%)

19:01
02/21/17
02/21
19:01
02/21/17
19:01
Hot Stocks
American Railcar enters Consulting Services pact with American Railcar Leasing »

According to a regulatory…

ARII

American Railcar

$46.03

-0.62 (-1.33%)

IEP

Icahn Enterprises

$54.95

-1.03 (-1.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

FB

Facebook

$133.72

0.19 (0.14%)

, TWTR

Twitter

$16.42

-0.2 (-1.20%)

18:57
02/21/17
02/21
18:57
02/21/17
18:57
Periodicals
MLB in talks with Facebook to stream one game per week, Reuters says »

Facebook (FB) is in…

FB

Facebook

$133.72

0.19 (0.14%)

TWTR

Twitter

$16.42

-0.2 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 23

    Feb

  • 28

    Feb

  • 06

    Mar

  • 19

    Mar

  • 28

    Mar

TX

Ternium

$23.69

0.13 (0.55%)

, TYEKF

ThyssenKrupp

18:50
02/21/17
02/21
18:50
02/21/17
18:50
Hot Stocks
Ternium to acquire CSA Siderurgica from ThyssenKrupp »

Ternium (TX) announced a…

TX

Ternium

$23.69

0.13 (0.55%)

TYEKF

ThyssenKrupp

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTB

Butterfield

$32.93

-0.08 (-0.24%)

, CG

Carlyle Group

$16.20

0.15 (0.93%)

18:30
02/21/17
02/21
18:30
02/21/17
18:30
Syndicate
Butterfield announces offering of 9.56M shares of common stock for holders »

The Bank of N.T.…

NTB

Butterfield

$32.93

-0.08 (-0.24%)

CG

Carlyle Group

$16.20

0.15 (0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

CPRT

Copart

$60.30

1.29 (2.19%)

18:09
02/21/17
02/21
18:09
02/21/17
18:09
Earnings
Copart reports Q2 adjusted EPS 58c, consensus 57c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

DAL

Delta Air Lines

$51.21

-0.02 (-0.04%)

18:07
02/21/17
02/21
18:07
02/21/17
18:07
Hot Stocks
Aeromexico says concludes Delta tender offer 'represents fair value' »

Grupo Aeromexico issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSS

Golden Star Resources

$0.99

0.0232 (2.40%)

18:04
02/21/17
02/21
18:04
02/21/17
18:04
Hot Stocks
Golden Star Resources sees FY17 gold production 255,000-280,000 »

Sees FY17 AISC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

GSS

Golden Star Resources

$0.99

0.0232 (2.40%)

17:57
02/21/17
02/21
17:57
02/21/17
17:57
Earnings
Golden Star Resources reports Q4 adjusted EPS 1c, consensus (1c) »

Reports Q4 gold revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

CY

Cypress Semiconductor

$13.12

0.22 (1.71%)

17:52
02/21/17
02/21
17:52
02/21/17
17:52
Hot Stocks
Cypress Semiconductor founder nominates two candidates for board »

T.J. Rodgers, founder and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 16

    Mar

XPO

XPO Logistics

$48.38

-0.84 (-1.71%)

, DEPO

Depomed

$15.77

-0.7 (-4.25%)

17:41
02/21/17
02/21
17:41
02/21/17
17:41
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: XPO…

XPO

XPO Logistics

$48.38

-0.84 (-1.71%)

DEPO

Depomed

$15.77

-0.7 (-4.25%)

WMGI

Wright Medical

$26.86

-0.1 (-0.37%)

HCLP

Hi-Crush Partners

$21.40

0.1 (0.47%)

RRGB

Red Robin

$47.50

-0.3 (-0.63%)

FSLR

First Solar

$36.62

1.78 (5.11%)

LNTH

Lantheus

$9.35

-0.1 (-1.06%)

GE

General Electric

$30.52

0.15 (0.49%)

TRCO

Tribune Media

$33.70

0.73 (2.21%)

SREV

ServiceSource

$6.05

0.22 (3.77%)

FUEL

Rocket Fuel

$2.55

0.08 (3.24%)

TXRH

Texas Roadhouse

$47.79

-0.45 (-0.93%)

WLL

Whiting Petroleum

$11.57

0.46 (4.14%)

TEX

Terex

$32.13

0.13 (0.41%)

PZZA

Papa John's

$85.63

-0.38 (-0.44%)

FE

FirstEnergy

$31.33

0.32 (1.03%)

PKD

Parker Drilling

GBT

Global Blood Therapeutics

$28.50

1.6 (5.95%)

CUZ

Cousins Properties

$8.66

0.01 (0.12%)

YUM

Yum! Brands

$67.67

-0.73 (-1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 01

    Mar

  • 07

    Mar

  • 07

    Mar

  • 14

    Mar

  • 26

    Apr

  • 09

    May

  • 22

    Feb

GLA

GlassBridge

, IMN

Imation

$0.77

-0.0091 (-1.17%)

17:41
02/21/17
02/21
17:41
02/21/17
17:41
Hot Stocks
GlassBridge implements name change, reverse stock split »

GlassBridge Enterprises…

GLA

GlassBridge

IMN

Imation

$0.77

-0.0091 (-1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HVT

Haverty Furniture

$22.95

0.4 (1.77%)

17:37
02/21/17
02/21
17:37
02/21/17
17:37
Earnings
Haverty Furniture reports Q4 EPS 51c, consensus 43c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

CUZ

Cousins Properties

$8.66

0.01 (0.12%)

17:36
02/21/17
02/21
17:36
02/21/17
17:36
Syndicate
Breaking Syndicate news story on Cousins Properties »

Cousins announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.